Core Insights - Duvakitug, an investigational human monoclonal antibody targeting TL1A, has shown durable clinical and endoscopic efficacy in patients with ulcerative colitis (UC) and Crohn's disease (CD) over a 44-week maintenance period following initial response in the induction phase [1][7] - The study results indicate that duvakitug has the potential to be a leading therapy for inflammatory bowel disease (IBD), with ongoing phase 3 studies to further evaluate its efficacy and safety [2][4] Study Details - The RELIEVE UCCD long-term extension study enrolled 130 patients who had responded to duvakitug in the induction study, with a maintenance period of 44 weeks where patients received either 450 mg or 900 mg doses every four weeks [2][12] - At week 44, 58% of patients on the 900 mg dose and 47% on the 450 mg dose achieved clinical remission in UC, while 55% on the 900 mg dose and 41% on the 450 mg dose achieved endoscopic response in CD [8] Safety and Tolerability - Both doses of duvakitug were well tolerated, with the most common adverse events being upper respiratory tract infection, nasopharyngitis, Crohn's disease, and hypertension, consistent with findings from the induction study [3][7] Industry Context - IBD is characterized by chronic inflammation of the gastrointestinal tract, with approximately 4.9 million cases globally, and the incidence is rising in several regions [5] - There is currently no cure for IBD, and treatment aims to induce and maintain remission while preventing flares [9]

Core Insights - Duvakitug, an investigational human monoclonal antibody targeting TL1A, has shown durable clinical and endoscopic efficacy in patients with ulcerative colitis (UC) and Crohn's disease (CD) over a 44-week maintenance period following initial response in the induction phase [1][7] Study Results - The RELIEVE UCCD long-term extension study enrolled 130 patients who initially responded to duvakitug in the induction study and were re-randomized to receive either 450 mg or 900 mg doses every four weeks for up to 58 weeks [2][12] - At week 44, 58% of patients receiving 900 mg and 47% receiving 450 mg achieved clinical remission in UC, while 55% of patients on 900 mg and 41% on 450 mg achieved endoscopic response in CD [8] Safety and Tolerability - Both doses of duvakitug were well tolerated, with the most common adverse events being upper respiratory tract infection, nasopharyngitis, Crohn's disease, and hypertension, consistent with findings from the induction study [3][7] Industry Context - IBD, affecting approximately 4.9 million people globally, is characterized by chronic inflammation of the gastrointestinal tract, with UC and CD being the most common forms [5] - There is currently no cure for IBD, and treatment aims to induce and maintain remission while preventing flares [9] Collaboration and Development - Sanofi and Teva are collaborating to co-develop and co-commercialize duvakitug, sharing development costs and profits in major markets, with Sanofi leading the phase 3 clinical development program [15]